NURIX THERAPEUTICS, INC. (NRIX)

Every figure this model derived for NRIX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-05-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 10,823,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-05-31
cash 284,233,000 CashAndCashEquivalentsAtCarryingValue 2026-05-31
current assets 456,481,000 AssetsCurrent 2026-05-31
current liabilities 72,020,000 LiabilitiesCurrent 2026-05-31
equity 402,627,000 StockholdersEquity 2026-05-31
ocf -293,704,000 NetCashProvidedByUsedInOperatingActivities 2026-05-31
revenue 36,766,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-05-31
sbc 39,650,000 ShareBasedCompensation 2026-05-31

The ratios

The figures themselves rather than their scores — what somebody looking up NRIX on one particular measure came for.

RatioValue
cash operating margin-851.14
current ratio7.78
current ratio reported6.34
deferred revenue growth-51.41
dilution pct29.14
fcf margin-828.28
growth cv0.97
operating margin-982.37
owner earnings margin-936.13
revenue growth-58.4
revenue growth per share-67.79
roic-241.0
rule of 40-1040.77
sbc pct revenue107.84

What to be careful about

What this model itself distrusts about NRIX's figures. Written by the derivation as it ran, not added afterwards.